| Dry Eye Syndromes
Miebo vs Eysuvis
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Miebo vs Eysuvis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEysuvis has a higher rate of injection site reactions vs Miebo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eysuvis but not Miebo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Miebo
Eysuvis
At A Glance
Topical (ophthalmic)
4 times daily
Semifluorinated alkane
Ophthalmic
Four times daily
Corticosteroid
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
Dosing
Dry Eye Syndromes Instill one drop four times daily into each affected eye; remove contact lenses prior to and for at least 30 minutes after administration.
Dry Eye Syndromes Instill one to two drops into each eye four times daily for up to two weeks.
Contraindications
- History of hypersensitivity reaction to perfluorohexyloctane
- Most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
Adverse Reactions
Most common (<4%) blurred vision, conjunctival redness
Premarketing studies hypersensitivity
Most common (>=5%) Instillation site pain
Serious Elevated intraocular pressure, optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing, secondary ocular infection from pathogens including herpes simplex, perforation of the globe
Pharmacology
Perfluorohexyloctane, a semifluorinated alkane, forms a monolayer at the air-liquid interface of the tear film that may reduce evaporation; the exact mechanism of action in dry eye disease is not known.
Corticosteroid that inhibits the inflammatory response by suppressing edema, fibrin deposition, capillary dilation, leukocyte migration, fibroblast proliferation, and collagen deposition, likely via inhibition of prostaglandin production through glucocorticoid receptor binding.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Miebo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (11/12)
Eysuvis
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
UnitedHealthcare
Miebo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Eysuvis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Miebo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Eysuvis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Thyroid Eye Disease (TED)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Eysuvis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EysuvisView full Eysuvis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.